{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:07:59Z","timestamp":1780513679367,"version":"3.54.1"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,5]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Psoriasis is a disease that commonly manifests in adolescence. Up to half of adults with psoriasis develop it before the age of 20. Topical formulations containing corticosteroids and\/or vitamin D3 analogs are recommended for treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>This phase II<\/jats:styled-content> study aimed to evaluate the safety, including any potential effect on the hypothalamic\u2013pituitary\u2013adrenal axis and calcium metabolism, and efficacy of fixed\u2010dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) (Cal\/BD<\/jats:styled-content>) gel in adolescents with psoriasis.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients aged 12 to <17\u00a0years, with at least mild psoriasis on the body and scalp, received topical Cal\/BD<\/jats:styled-content> gel once daily for \u22648\u00a0weeks. Safety response criteria included adverse drug reactions [ADR<\/jats:styled-content>s; any adverse event (AE<\/jats:styled-content>) possibly or probably related to treatment as determined by the investigator; a primary response criterion] and AE<\/jats:styled-content>s (a secondary response criterion). Only treatment\u2010emergent AE<\/jats:styled-content>s (events that occurred after the first application of Cal\/BD<\/jats:styled-content> gel or events which started before this and increased in intensity after the first application of Cal\/BD<\/jats:styled-content> gel) are presented here. Efficacy response criteria included controlled disease, by physician's global assessment of disease severity (PGA<\/jats:styled-content>), following Cal\/BD<\/jats:styled-content> gel treatment.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 107 patients (median age 14\u00a0years; range 12\u201316) were enrolled and treated. Eight ADR<\/jats:styled-content>s were observed in 7 (7%) patients and 38 (36%) patients experienced \u22651 AE<\/jats:styled-content>. The most common AE<\/jats:styled-content>s were headache [6 (6%) patients], nasopharyngitis [6 (6%) patients] and blood parathyroid hormone increased [4 (4%) patients]. One severe AE<\/jats:styled-content> was reported (attempted suicide) but was considered unrelated to treatment. At the end of treatment, 58% of patients had controlled disease on the body and 69% on the scalp according to PGA<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>In this uncontrolled phase II<\/jats:styled-content> study, Cal\/BD<\/jats:styled-content> gel was well tolerated and effective for treating scalp and body psoriasis in adolescents.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.16077","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T14:23:57Z","timestamp":1573655037000},"page":"1098-1104","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of topical, fixed\u2010dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial"],"prefix":"10.1111","volume":"34","author":[{"given":"L.F.","family":"Eichenfield","sequence":"first","affiliation":[{"name":"University of California San Diego and Rady Children's Hospital San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Marcoux","sequence":"additional","affiliation":[{"name":"Sainte\u2010Justine University Hospital Center Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kurvits","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Liljedahl","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503023320907"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-006-0703-z"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09593.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.12.1537"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854"},{"key":"e_1_2_7_9_1","first-page":"187","article-title":"Prevalence of psoriasis in children and adolescents in the United States: a claims\u2010based analysis","volume":"17","author":"Paller AS","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01489.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0137-1"},{"key":"e_1_2_7_12_1","first-page":"890860","article-title":"Self\u2010management in daily life with psoriasis: an integrative review of patient needs for structured education","volume":"2012","author":"Rasmussen GS","year":"2012","journal-title":"Nurs Res Pract"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16326"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10996.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.161"},{"key":"e_1_2_7_16_1","unstructured":"FDA.Taclonex topical suspension prescribing information.2017. URLhttp:\/\/taclonex.com\/pdf\/TTS_USPI_June_2017.pdf(last accessed: 04 June 2019)."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12429"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13235"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000073560"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203030-00001"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031237"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6888.1344-b"},{"key":"e_1_2_7_23_1","first-page":"278","article-title":"Psoriasis treatment with vitamin D derivatives","volume":"11","author":"Menne T","year":"1992","journal-title":"Semin Dermatol"},{"key":"e_1_2_7_24_1","first-page":"882","article-title":"Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic\u2010pituitary\u2010adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non\u2010controlled, 8\u2010week trial","volume":"12","author":"Silver S","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2010.03.012"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:41:59Z","timestamp":1693820519000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/jdv.16077"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16077","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"2019-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}